NewCelX is a biopharmaceutical company that uses regenerative cell therapies and novel active pharmaceutical ingredients to treat type 1 diabetes and other CNS disorders, built on a human pluripotent stem cell platform for scalable cell expansion and precise differentiation. The company was formed by the merger of Kadimastem Ltd. and NLS Pharmaceutics Ltd.
IsletRx, NewCelX's lead program, is a stem-cell-derived therapy for insulin-dependent type 1 diabetes designed to restore insulin production through off-the-shelf cell replacement. It integrates micro-encapsulation technology that protects the islet cells from the host immune system without immunosuppressive drugs. IsletRx is designed to remove the need for continuous blood sugar monitoring and repeated insulin injections.
Similar Companies

SymbioCellTech
symbiocelltech.com

Xostem

Encellin
encellin.com
Celvive
Isla Technologies

Pathfinder Cell Therapy

Cellino
cellinobio.com

Hepatx
hepatx.com

PharmaCyte Biotech
pharmacyte.com

StimCell Energetics
cellmedx.com

MelliCell
mellicell.com

Celularity
celularity.com

Excellos
excellos.com

Corxel Pharmaceuticals
corxelbio.com

Cellebration Life Sciences

Celltex Therapeutics
celltexbank.com

Tr1x
tr1x.bio

Cell Care Therapeutics
cell-care.com

Xcell Biosciences
xcellbio.com

Vericel
vcel.com
Quick Facts
Who are NewCelX's competitors?
Companies similar to NewCelX include SymbioCellTech, Xostem, Encellin and Celvive.
When was NewCelX founded?
NewCelX was founded in 2025.
Where is NewCelX's headquarters located?
NewCelX's headquarters is located in Kloten, CH.
Classification
- Industry
- Ownership
- Technology
- Geographic Exposure
- Revenue
- Customer
- Also Known As
- NewCelX Ltd
- NLS Pharmaceutics Ltd.
- Headquarters
- Hohstrasse 1
- Kloten, 8302
- CH
- SEC CIK
- 0001783036
